K. pneumoniae

K. pneumoniae Full Name

Klebsiella pneumoniae

K. pneumoniae Introduction

Klebsiella pneumoniae is a Gram-negative, encapsulated, non-motile bacterium belonging to the family Enterobacteriaceae that has emerged as one of the most clinically significant opportunistic pathogens in healthcare settings worldwide. This organism is a common colonizer of the human gastrointestinal tract and nasopharynx, where it typically exists as a commensal, but it possesses the capacity to cause severe infections when host defenses are compromised or when it gains access to normally sterile body sites. K. pneumoniae is responsible for a diverse spectrum of clinical syndromes including hospital-acquired and ventilator-associated pneumonia, urinary tract infections, bloodstream infections, surgical site infections, and liver abscesses, with particularly severe outcomes in immunocompromised patients, diabetics, alcoholics, and those with underlying pulmonary disease. The organism has gained notoriety as a member of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), a group of bacteria that exhibit high rates of antimicrobial resistance and are responsible for the majority of healthcare-associated infections. The global dissemination of multidrug-resistant (MDR) and extensively drug-resistant (XDR) K. pneumoniae strains, particularly those producing extended-spectrum beta-lactamases (ESBLs) and carbapenemases, has created a public health crisis with limited therapeutic options.

The virulence of K. pneumoniae is attributed to multiple factors that enable colonization, immune evasion, and tissue damage. The polysaccharide capsule (K antigen) is the primary virulence determinant, forming a thick mucoid layer that protects bacteria from phagocytosis, complement-mediated killing, and antimicrobial peptides. Over 80 capsular (K) types have been identified based on antigenic diversity, with certain types (particularly K1 and K2) associated with hypervirulent strains that cause community-acquired invasive infections, including pyogenic liver abscesses predominantly reported in Asia. The hypermucoviscosity phenotype, assessed by the string test (formation of a viscous string >5 mm when a colony is stretched with an inoculation loop), correlates with enhanced capsule production and increased virulence. Lipopolysaccharide (LPS) O-antigens contribute to serum resistance and complement evasion, while type 1 and type 3 fimbriae (encoded by fim and mrk gene clusters, respectively) mediate adhesion to host tissues and abiotic surfaces, facilitating colonization and biofilm formation on medical devices. Siderophores including enterobactin, yersiniabactin, salmochelin, and aerobactin enable iron acquisition in the iron-limited host environment, with aerobactin particularly associated with hypervirulent strains. Additional virulence factors include outer membrane proteins, secretion systems, and various enzymes that contribute to tissue invasion and damage.

The emergence and global spread of carbapenem-resistant K. pneumoniae (CR-KP) represents one of the most pressing antimicrobial resistance threats of the 21st century. Carbapenemases, including KPC (Klebsiella pneumoniae carbapenemase), NDM (New Delhi metallo-beta-lactamase), OXA-48-like enzymes, and VIM/IMP metallo-beta-lactamases, confer resistance to carbapenems, which were previously considered last-resort antibiotics for treating MDR Gram-negative infections. These carbapenemase genes are typically carried on mobile genetic elements (plasmids, transposons) that facilitate horizontal transfer among Enterobacteriaceae, accelerating the spread of resistance. CR-KP infections are associated with mortality rates ranging from 30-70% in bacteremic patients, reflecting both the severity of underlying conditions in affected patients and the limited treatment options available. Therapeutic approaches for CR-KP infections include combination regimens incorporating polymyxins (colistin, polymyxin B), tigecycline, aminoglycosides, fosfomycin, and newer agents such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam, although resistance to these agents has already emerged. Infection prevention and control measures, including active surveillance, contact precautions, environmental cleaning, and antimicrobial stewardship, are essential for containing the spread of CR-KP in healthcare settings.

Alternate Names for K. pneumoniae

Bacteria; Proteobacteria; Gamma Proteobacteria; Enterobacteriales; Enterobacteriaceae; Klebsiella; K. pneumoniae; Klebsiella pneumoniae; K. oxytoca; K. terrigena; K. pneumoniae; Klebsiella pneumoniae; Klebsiella; pneumoniae;

• Humanized Control Antibodies for Infectious Disease Diagnostics
• Humanized Control Antibodies for Infectious Disease Diagnostics
• Humanized Control Antibodies for Infectious Disease Diagnostics
• Humanized Control Antibodies for Infectious Disease Diagnostics